Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer Article

Belani, Chandra P, Nemunaitis, John J, Chachoua, Abraham et al. (2013). Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer . CANCER BIOLOGY & THERAPY, 14(7), 557-563. 10.4161/cbt.24598

Open Access Industry Collaboration

cited authors

  • Belani, Chandra P; Nemunaitis, John J; Chachoua, Abraham; Eisenberg, Peter D; Raez, Luiz E; Cuevas, J Daniel; Mather, Cecile B; Benner, Rebecca J; Meech, Sandra J

sustainable development goals

authors

publication date

  • July 1, 2013

webpage

published in

keywords

  • 1ST-LINE TREATMENT
  • EGFR
  • II TRIAL
  • Life Sciences & Biomedicine
  • Oncology
  • PF-3512676
  • Science & Technology
  • TLR9 AGONISTS
  • Toll-like receptor 9
  • carcinoma
  • epidermal growth factor
  • erlotinib
  • non-small cell lung cancer
  • receptor

Digital Object Identifier (DOI)

publisher

  • LANDES BIOSCIENCE

start page

  • 557

end page

  • 563

volume

  • 14

issue

  • 7